Comprehensive molecular profiling of sarcomas in adolescent and young adult patients: Results of the EORTC SPECTA-AYA international proof-of-concept study

•AYA cancers have been neglected by molecular profiling initiatives.•Most AYA sarcomas of adequate sample quality have identifiable actionable mutations.•Clinical evidence to support personalised treatment for AYAs is weak or absent.•International molecular profiling is feasible and necessary to fill research gaps.•More effort is needed to enable AYA patients' access to molecularly focused trials.